IP Library Patent Application 12466663
Patent Application
App. No. 12/466,663

Method of Analyzing a BRCA2 Gene in a Human Subject

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/466,663
Abstract

Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2 (omi 1-5) and the ten polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene and/or protein sequence, determine the presence of a normal sequence, and of mutations of BRCA2. This invention is also related to a method of performing gene therapy with BRCA2 (omi 1-5) coding sequences or fragments thereof. This invention is further related to protein therapy with BRCA2 (omi 1-5) proteins or their functional equivalents.

Claims (21)

1 - 60 . (canceled)

61 . An isolated nucleic acid comprising:

(a) 18 contiguous nucleotides spanning the 3′ exon/intron junction of exon 15 according to FIG. 2D ;

(b) 18 contiguous nucleotides spanning the 5′ exon/intron junction of exon 16 according to FIG. 2D ;

(c) the nucleotide

sequence 5′-GTGTTCTCATAAACAGgtatgtgt-3′;

(d) the nucleotide

sequence 5′-tttttcttttttgtgtgtgtttattttgtgtagCTGTA

TACGTATGGCGTTTC-3′;

(e) the nucleotide sequence of exon 15 and having the nucleotide

sequence 5′- GTGTTCTCATAAACAGgtatgtgt-3′;

(f) the nucleotide sequence of SEQ ID NO:2; or

(g) the nucleotide sequence of SEQ ID NO:3.

62 . A method of amplifying exon 15 of a BRCA2 gene, wherein the sequence of the last 16 nucleotides of exon 15 is 5′-GTGTTCTCATAAACAG-3′, the method comprising:

obtaining a sample containing genomic DNA from a human subject;

amplifying exon 15 or two or more portions thereof from said genomic DNA.

63 . The method of claim 62 , wherein said amplifying step comprises PCR to obtain (1) a first isolated nucleic acid comprising the 5′ intron/exon junction of exon 15 according to SEQ ID NO:2 and (2) a second isolated nucleic acid comprising the 3′ exon/intron junction of exon 15 according to SEQ ID NO:2.

64 . A method of amplifying exon 16 of a BRCA2 gene, wherein the sequence of the first 20 nucleotides of exon 16 is 5′-CTGTATACGTATGGCGTTTC-3′, the method comprising:

obtaining a sample containing genomic DNA from a human subject;

amplifying exon 16 or two or more portions thereof from said genomic DNA.

65 . The method of claim 64 , wherein said amplifying step comprises PCR to obtain (1) a first isolated nucleic acid comprising the 5′ intron/exon junction of exon 16 according to SEQ ID NO:3 and (2) a second isolated nucleic acid comprising the 3′ exon/intron junction of exon 16 according to SEQ ID NO:3.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jul 10, 2023
From: JPMORGAN CHASE BANK, N.A.
To: MYRIAD GENETICS, INC.; CRESCENDO BIOSCENCE, INC.; MYRIAD RBM, INC.; MYRIAD WOMEN'S HEALTH, INC.
Reel/Frame 064239/0091 →
SECURITY INTEREST Recorded Dec 27, 2016
From: MYRIAD GENETICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 041198/0578 →
MERGER Recorded Jun 11, 2010
From: GENE LOGIC ACQUISITION CORP.
To: GENE LOGIC, INC.
Reel/Frame 024521/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2010
From: MURPHY, PATRICIA D; WHITE, MARGA B; RABIN, MARK B; OLSON, SHERI J; ESKANDARI, TARA; SCHRYER, BRENDA; PARK, MICHAEL; YOSHIKAWA, MATTHEW; JACKSON, GEOFFREY M
To: ONCORMED, INC.
Reel/Frame 024521/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2010
From: ORE PHARMACEUTICALS, INC.
To: MYRIAD GENETICS, INC.
Reel/Frame 024524/0016 →
CHANGE OF NAME Recorded Jun 11, 2010
From: GENE LOGIC, INC.
To: ORE PHARMACEUTICALS, INC.
Reel/Frame 024521/0822 →
MERGER Recorded Jun 11, 2010
From: ONCORMED, INC.
To: GENE LOGIC ACQUISITION CORP.
Reel/Frame 024521/0692 →